Shares of Clovis Oncology (NASDAQ:CLVS) shot up 6.4% on Tuesday . The stock traded as high as $17.61 and last traded at $17.41. 1,516,821 shares were traded during trading, a decline of 14% from the average session volume of 1,755,169 shares. The stock had previously closed at $16.36.

Several brokerages have weighed in on CLVS. BidaskClub raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Piper Jaffray Companies lifted their price target on Clovis Oncology to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, February 27th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $27.00 price target on shares of Clovis Oncology in a research report on Wednesday, February 27th. Finally, SunTrust Banks lifted their price target on Clovis Oncology to $35.00 and gave the company a “buy” rating in a research report on Wednesday, February 27th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $33.89.

The stock has a market cap of $894.19 million, a PE ratio of -2.46 and a beta of 1.89. The company has a debt-to-equity ratio of 8.04, a current ratio of 4.39 and a quick ratio of 4.15.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.17. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. The company had revenue of $33.12 million for the quarter, compared to analysts’ expectations of $32.10 million. During the same period last year, the firm earned ($1.38) EPS. The firm’s revenue for the quarter was up 78.8% on a year-over-year basis. On average, research analysts expect that Clovis Oncology will post -6.75 EPS for the current year.

In related news, insider Lindsey Rolfe sold 1,731 shares of Clovis Oncology stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $29.29, for a total value of $50,700.99. Following the transaction, the insider now directly owns 16,497 shares in the company, valued at approximately $483,197.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James C. Blair sold 17,056 shares of Clovis Oncology stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $27.79, for a total value of $473,986.24. Following the completion of the transaction, the director now owns 13,439 shares in the company, valued at $373,469.81. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,782 shares of company stock worth $576,755. 8.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE grew its holdings in shares of Clovis Oncology by 8.4% in the 1st quarter. US Bancorp DE now owns 8,820 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 681 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Clovis Oncology by 0.9% in the 3rd quarter. Teachers Advisors LLC now owns 144,561 shares of the biopharmaceutical company’s stock worth $4,246,000 after acquiring an additional 1,278 shares during the last quarter. Creative Planning grew its holdings in shares of Clovis Oncology by 1.1% in the 1st quarter. Creative Planning now owns 139,550 shares of the biopharmaceutical company’s stock worth $3,464,000 after acquiring an additional 1,513 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Clovis Oncology by 93.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,146 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,519 shares during the last quarter. Finally, Pearl River Capital LLC acquired a new position in shares of Clovis Oncology in the 1st quarter worth $40,000.

WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/clovis-oncology-clvs-shares-up-6-4/3018061.html.

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Further Reading: How to track put option volume

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.